Korean Food and Drug Administration is proud to announce the development of a new Hepa B drug Levovir Capsule; the new drug that will be made available in the market for patients treating hepa B infections.
The drug, developed by Bukwang Pharmaceuticals, Co., was a product of an intensive 10 years of clinical research and drug development which costs about $96 million since day 1.
Levovir Capsule is the first local drug that was approved for the treatment of the above disease. Clevudine, Levovir's main ingredient developed in the United States, is legally sold and developed by Bukwang Pharmaceuticals, Co. Please go to The Korean Herald for more information.
---
More Blog Topics at:
http://hivaidsresourcecenter.blogspot.com/
http://juliusbio.blogspot.com/
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment